For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- JACDS to Clarify Its Stance on Points Granted for Copayments of Dispensing Fees
January 31, 2011
- Roche Diagnostics Obtains Approval for HER2 Gene Amplification Kit
January 31, 2011
- No. of Prescriptions Filled by GROWELL Up Sharply Due to Point Granting
January 31, 2011
- Takara Bio to Globally Develop HF10 Licensed from M's Science
January 31, 2011
- Xyzal Ranked No. 1 in GP Market: RepTrack Survey
January 31, 2011
- Takeda, Kyoto Univ. to Collaborate for CNS Drug Discovery
January 31, 2011
- aRigen Licenses Novel Anti-MRSA to GCC in South Korea
January 31, 2011
- Kyowa Kirin Licenses AMG827 from Amgen
January 31, 2011
- Tokuhon to Launch 2 Adhesive NSAIDs in China
January 31, 2011
- Daiichi Sankyo, ArQule Begin PIII Trial of ARQ197
January 31, 2011
- JACDS to Call on Members to Temporarily Refrain from Offering Points for Dispensing Services
January 24, 2011
- Mr Hosokawa Reappointed Health Minister
January 24, 2011
- LSIP Signs 1st Agreements for Patents on Apoptosis, Stem Cells
January 24, 2011
- Pfizer Applies for Prevnar 13 in Adult Patients in US, Europe
January 24, 2011
- Takeda Licenses Biomarker for Alzheimer's Disease from Zinfandel
January 24, 2011
- Prospects for Simultaneous Global Development: 4
January 24, 2011
- Ono Enters Target Discovery Agreement with BioFocus for Autoimmune Disease
January 24, 2011
- Minodronate vs Raloxifene to Be Compared in IIT
January 24, 2011
- Astellas Expands Marketing Territory for Eligard
January 24, 2011
- Office of Medical Innovation to Begin Full Operation
January 24, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…